Skip to contentH
Haemonetics Corp
H
HAEHaemonetics Corp Q1 2024 · 10-Q
Revenue$311.33M$311.33M+19.1% vs Q1 2023 Net Income$41.04M$41.04M+106.5% vs Q1 2023 EPS Diluted$0.80$0.80+110.5% vs Q1 2023 Gross Profit$167,265,000+17.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Haemonetics Corp · CIK 313143 · Engraved from SEC EDGAR
Operating Cash Flow$19,086,000−54.5% Free Cash Flowderived$11,405,000N/M Margins · derivedGross margin53.7%−0.7 pt vs Q1 2023
Operating margin17.2%+5.5 pt vs Q1 2023
Net margin13.2%+5.6 pt vs Q1 2023
ended Jul 1, 2023 · filed Aug 8, 2023 · 38 d after period end